论文信息 - Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2 - 字舞流文

Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2

P. Sonneveld | V. V. D. van der Velden | M. Mohty | M. Béné | P. Moreau | M. Macro | F. Rigat | M. Delforge | J. Corre | J. Vermeulen | B. Arnulf | C. D. de Boer | F. Offner | A. Broyl | S. Wuillème | L. Karlin | A. Perrot | A. Stoppa | C. Hulin | M. Levin | S. Klein | S. Zweegman | N. V. D. van de Donk | D. Caillot | J. Lambert | M. Krevvata | K. Jie | T. Kampfenkel | V. Vanquickelberghe | Shiyi Yang | Hervé Avet Loiseau | V. H. van der Velden